Therefore, treatment-refractory HR+, HER2-, advanced breast cancer patients may undergo F1CDx analysis to determine if they possess a PIK3CA mutation and therefore may benefit from alpelisib treatment. The gene discussed is PIK3CA; the disease is breast cancer.